| scholarly article | Q13442814 |
| P2093 | author name string | Naren L Banik | |
| Supriti Samantaray | |||
| Varduhi H Knaryan | |||
| Swapan K Ray | |||
| Jonathan T Butler | |||
| P2860 | cites work | Immunofluorescent labeling of increased calpain expression and neuronal death in the spinal cord of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice | Q44820160 |
| Redox cycling of MPP+: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase. | Q45940806 | ||
| Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease | Q46691979 | ||
| Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. | Q46884563 | ||
| MPTP produces a mosaic-like pattern of terminal degeneration in the caudate nucleus of dog. | Q48194614 | ||
| Neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the cat. Tyrosine hydroxylase immunohistochemistry | Q48343791 | ||
| Detection of mRNAs and alternatively spliced transcripts of dopamine receptors in rat peripheral sensory and sympathetic ganglia | Q48456138 | ||
| The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter | Q48474982 | ||
| Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine | Q48477579 | ||
| An improved fluorimetric assay for brain monoamine oxidase | Q48483717 | ||
| Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects | Q48566508 | ||
| Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. | Q48601969 | ||
| Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism | Q48614154 | ||
| Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart | Q48644682 | ||
| Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase | Q48681443 | ||
| Neurochemical and behavioral effects of systematic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat | Q48682433 | ||
| Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? | Q48954833 | ||
| The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia. | Q55479576 | ||
| Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis | Q22242250 | ||
| α-Synuclein in Lewy bodies | Q27860680 | ||
| Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
| Alpha-synuclein and neurodegenerative diseases | Q28204386 | ||
| Chronic parkinsonism secondary to intravenous injection of meperidine analogues | Q28323857 | ||
| Parkinson's disease: mechanisms and models | Q29547424 | ||
| The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety | Q32133943 | ||
| Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium | Q33191656 | ||
| D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity | Q34215774 | ||
| Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells | Q34367534 | ||
| Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra | Q34446321 | ||
| Protocol for the MPTP mouse model of Parkinson's disease | Q34614573 | ||
| Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration | Q35916447 | ||
| The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats | Q35925804 | ||
| A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry | Q36226890 | ||
| A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q37343442 | ||
| Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity | Q37683630 | ||
| Spinal dopamine mechanisms and primary sensory symptoms in Parkinson's disease | Q39509889 | ||
| Calpain activation in apoptosis of motoneurons in cell culture models of experimental parkinsonism | Q40208453 | ||
| Regional localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) uptake: Mismatch between its uptake and neurotoxic sites | Q41974915 | ||
| Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. | Q42468902 | ||
| Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals | Q42493232 | ||
| Biodistribution study of [99mTc] TRODAT-1 alone or combined with other dopaminergic drugs in mice with macroautoradiography | Q44076211 | ||
| Calcium channel agonist, (±)-Bay K8644, causes a transient increase in striatal monoamine oxidase activity in Balb/c mice | Q44427020 | ||
| Calcium channel agonist, (+/-)-Bay K8644, causes an immediate increase in the striatal 1-methyl-4-phenylpyridinium level following systemic administration of the dopaminergic neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, in Balb/c mice | Q44506297 | ||
| Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. | Q44746550 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | parkinsonian syndrome | Q1531991 |
| Parkinson's disease | Q11085 | ||
| P304 | page(s) | 1309-1320 | |
| P577 | publication date | 2007-11-23 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP. | |
| P478 | volume | 104 |
| Q38295414 | Calpain inhibition protected spinal cord motoneurons against 1-methyl-4-phenylpyridinium ion and rotenone |
| Q43463927 | Changes of gene expression profiles in the cervical spinal cord by acupuncture in an MPTP-intoxicated mouse model: Microarray analysis |
| Q37384896 | Critical role of calpain in spinal cord degeneration in Parkinson's disease |
| Q36021445 | Inhibition of Calpain Activation Protects MPTP-Induced Nigral and Spinal Cord Neurodegeneration, Reduces Inflammation, and Improves Gait Dynamics in Mice |
| Q43294352 | Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO). |
| Q48224687 | Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease |
| Q50067933 | Role of catalpol in ameliorating the pathogenesis of experimental autoimmune encephalomyelitis by increasing the level of noradrenaline in the locus coeruleus. |
| Q33686439 | SNJ-1945, a calpain inhibitor, protects SH-SY5Y cells against MPP(+) and rotenone |
| Q37851642 | Spinal cord and parkinsonism: Neuromorphological evidences in humans and experimental studies |
| Q48685237 | The vincamine derivative vindeburnol provides benefit in a mouse model of multiple sclerosis: effects on the Locus coeruleus |
| Q37880260 | Tracking extranigral degeneration in animal models of Parkinson’s disease: quest for effective therapeutic strategies |
Search more.